Exposure to Oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine

  • Peltoniemi M
  • Saari T
  • Hagelberg N
 et al. 
  • 18


    Mendeley users who have this article in their library.
  • 21


    Citations of this article.


This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2mg/kg S-ketamine after pretreatments with oral ticlopidine (250mg twice daily), itraconazole (200mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC 0-) of oral ketamine by 2.4-fold (P< 0.001), whereas itraconazole treatment did not increase the exposure to S-ketamine. The ratio of norketamine AUC 0-to ketamine AUC 0-was significantly decreased in the ticlopidine (P 0.001) and itraconazole phases (P = 0.006) as compared to placebo. In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P 0.05). The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine. © 2011 american society for Clinical Pharmacology and therapeutics.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Teijo SaariTurun yliopisto

  • M. A. Peltoniemi

  • N. M. Hagelberg

  • P. Reponen

  • M. Turpeinen

  • K. Laine

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free